Treatment with antibodies that block inhibitory receptors, such as cytotoxic T lymphocyte associated protein 4 (CTLA-4), programmed death receptor 1 (PD-1), or its ligand PD-L1, can lead to durable complete responses in some patients depending on the cancer type (1). The gene discussed is CTLA4; the disease is cancer.